Discover 1,609 paid clinical trials in Raleigh, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,609
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
for
Diffuse Midline Glioma, H3 K27-Altered,
Location: Durham NC, Washington D.C. DC, Baltimore MD,
Sponsor: Children's Oncology Group
Sex: All
Age: 1 - 21
Code: NCT04870944
Phase1, Phase2, Recruiting
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
for
Advanced Solid Tumor
Location: Durham NC, Cincinnati OH, Cleveland OH, New York NY,
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Sex: All
Age: 18+
Code: NCT06859762
Phase1, Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
for
Ovarian Neoplasms, Breast Neoplasms,
Location: Durham NC, Glen Burnie MD, Philadelphia PA, New York NY,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07213791
Phase1, Recruiting
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
for
Castration-Sensitive Prostate Carcinoma,
Location: Durham NC, Pinehurst NC, Richmond VA, Tappahannock VA,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: Male
Age: 18+
Code: NCT06931340
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
for
Acute Myeloid Leukemia (AML)
Location: Durham NC, Chapel Hill NC, Charlottesville VA,
Sponsor: Kura Oncology, Inc.
Sex: All
Age: 18+
Code: NCT07007312
Phase3, Recruiting
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
for
Progressive Metastatic Castrate Resistant Prostate Cancer
Location: Durham NC, Atlanta GA, Cleveland OH, Denver CO,
Sponsor: Novartis Pharmaceuticals
Sex: Male
Age: 18+
Code: NCT07206056
Phase1, Phase2, Recruiting
Intent of Surgery for IPMN
for
Intraductal Papillary Mucinous Neoplasm
Location: Durham NC, Baltimore MD, New York NY, Boston MA,
Sponsor: NYU Langone Health
Sex: All
Age: 18+
Code: NCT07216521
Recruiting
Safety of RSV Preventive Monoclonal Antibody
for
Fever, Adverse Event Following Immunisation
Location: Durham NC, Atlanta GA, Cincinnati OH, New York NY,
Sponsor: Duke University
Sex: All
Age: 0
Code: NCT07158814
Recruiting
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)